Skip to content

VIC NEWS

From the blog

VIC-Pub-11323

Bifunctional cancer cell–based vaccine concomitantly drives direct tumor killing and antitumor immunity

VIC Update 1223

Optimized ACE2 decoys neutralize antibody-resistant SARS-CoV-2 variants through functional receptor mimicry and treat infection in vivo

DAVID_ALAGPULINSA

Keystone Symposium selects Dr. Alagpulinsa for 2023 Fellows Program

eOD-GT8-60mer-WEB

Novel HIV vaccine approach shows promise in first-in-human clinical trial

image

Dr. Poznansky Gives an Invited Research Talk about Latest Advances at VIC

Screen Shot 2022-11-09 at 1.21.39 PM

Investigating Cancer Immunotherapy Effects on COVID-19 Outcomes

new approaches to needleless vaccine delivery

New approaches to needle-less vaccine delivery

Screen Shot 2022-11-03 at 2.46.25 PM

A novel cuproptosis-related immune checkpoint gene signature identification and experimental validation in hepatocellular carcinoma

pHLIP-STING2

Cancer-seeking molecular delivery system could boost immunotherapy drug, research finds

VIC-polo-VII-2022-poster

VIC lab members enjoying social gatherings this summer.

DSC_1857VIC Update

Undergraduates enjoy a successful summer internship at VIC!

Cancer-Cell-Cover

Precise reconstruction of the TME using bulk RNA-seq and a machine learning algorithm trained on artificial transcriptomes.

unnamed

Evaluation of a Human T Cell-Targeted Multi-Epitope Vaccine for Q Fever in Animal Models of Coxiella burnetti Immunity.

VIC-NEWs-WMIF-MGH

2022 WMIF | The Dr. Is In | Leveraging Novel Mechanisms for Vaccine and Immunotherapy Development

David-V-leaving-party-5-26-22

David Verrill Goodbye Event

image001

EpiVax and Massachusetts General Hospital Advance on T cell-Targeted Epitope Vaccine for Q Fever

image002

COVID Vaccines, Therapeutics, Variants, Long COVID, Ability To Tackle the Next Pandemic

Screen-Shot-2022-04-26-at-12.52.09-PM

A new platform for immunotherapeutic RNA delivery to cancer cells

new-immune-cell-soldier-could-be-a-good-target-for-immunotherapy-360799-1280x720

Immune cell ‘Soldier’ identified as potential target for immunotherapy

VIC-News-Post-Dual-Drug-Treatment

Dual-drug treatment offers promise for advanced melanoma patients

Screen Shot 2022-04-02 at 6.05.44 PM

Novel drug combination may boost chemoimmunotherapy response in bladder cancer patients

1647962885954

Two-pronged immunotherapy treatment tested for effectiveness against glioblastomas

COH.DrDiamond-17LO

Recent data published indicates great hope in a newly developed COVID-19 vaccine

VIC-2-image

Restoring p53 function with mRNA nanoparticles and immune checkpoint blockade to enhance immunotherapy

Ukraine-Flag

181 Nobel Laureates condemn Vladimir Putin’s unprovoked and brutal invasion of Ukraine.

image001

Exciting research reveals new potential in investigating “hybrid immunity” against Covid-19 and evolving variant

coronavirusgraphic072920

Three pillars of pandemic preparedness to end this one while preparing for the next

Voltron-News-Img

Voltron Therapeutics, a Laidlaw Venture Partner, Announces Selection of Therapeutic Targets for Immuno-Oncology Program

VIC-News-1312022-2

B cells do more than just help fight infection: a new study shows that they can support tissue repair and regeneration after injury

19A

FASEB Journal publication from VIC’s Dr. Sîrbulescu and her team.

Prof.-Dulcie-V-Coleman-Lecture-Cover

Mark Poznansky and VIC hosted the annual Professor Dulcie V. Coleman Lecture

Laisa-and-Jeff

Clofazimine for babesiosis: preclinical data support a clinical trial

COVID-RECOVERY-NOAH-&-IZZY

IBD Patients Like Eric Prompt More Questions About COVID-19

Politico-Cover-Image

A Virus-Hunter’s Advice on Dealing with China’s Resistance on Covid

Philanthropic support is critical to VIC’s success